Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes

@inproceedings{Liao2016SodiumGlucoseC2,
  title={Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes},
  author={Xin Liao and Xuemei Wang and Haopeng Li and Ling Zhi Li and Guohao Zhang and Mengliu Yang and Lei Yuan and Hua Liu and Gangyi Yang and Lin Gao},
  booktitle={Scientific reports},
  year={2016}
}
ZAG has recently been characterized as a potent metabolic regulator, but the effect of anti-diabetic agents on ZAG in humans remains unknown. Our aim was to study the effects of SGLT2 inhibitor on circulating ZAG and ADI in nT2DM. 162 subjects with nT2DM were treated by a placebo or DAPA. After 3-months of DAPA therapy, HbA1c, FBG, 2h-PBG, FFA, TG, blood pressure, BMI, WHR, body weight, FAT%, FINS, and HOMA-IR in T2DM patients decreased significantly, whereas HDL-C was significantly increased… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 44 references

a systematic review and network meta-analysis

  • Goring, S. et al. Dapagliflozin compared with other oral anti monotherapy
  • Diabetes Obes Metab 16, 433–442
  • 2014

cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes

  • Yang, M. et al. Zinc-alpha2-glycoprotein is associated with humans, is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration
  • Diabetes Care 36, 1074–1082
  • 2013

Similar Papers

Loading similar papers…